Bispecific fusion antibodies with enhanced serum half-life

Details for Australian Patent Application No. 2005250216 (hide)

Owner Domantis Limited

Inventors Holt, Lucy J.; Tomlinson, Ian M.

Agent Davies Collison Cave

Pub. Number AU-B-2005250216

PCT Pub. Number WO2005/118642

Priority 60/632,361 02.12.04 US; 60/576,271 01.06.04 US

Filing date 31 May 2005

Wipo publication date 15 December 2005

Acceptance publication date 10 December 2009

International Classifications

C07K 16/46 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - Hybrid immunoglobulins

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

C07K 16/00 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/18 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from animals or humans

C07K 16/44 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material not provided for elsewhere

Event Publications

14 December 2006 PCT application entered the National Phase

  PCT publication WO2005/118642 Priority application(s): WO2005/118642

10 December 2009 Application Accepted

  Published as AU-B-2005250216

8 April 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005250219-Oligonucleotides for cancer diagnosis

2005250212-Improvements in product security